This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on ISI (9)  • Contact me when this article is cited  Related Content  • Similar articles in this journal

Arch Ophthalmol. 1999;117:966-968.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Scleritis is an uncommon clinical entity that is frequently resistant to standard forms of topical and systemic treatment. The use of subconjunctival injections of corticosteroids for treating noninfectious, nonnecrotizing anterior scleritis has been discouraged in the literature for several decades because of a presumed risk for scleral thinning and globe perforation.^1-2 The first report opposing this advice was published in 1995³ and described 20 patients receiving injections during a 5-year period. Most had beneficial responses, and none developed scleral thinning or perforation.

The senior author (F.S.B.) of this report has used subconjunctival steroids as primary therapy for anterior scleritis for 28 years and has not seen significant scleral thinning or perforation as a result of an injection. We present this small case series to add supportive documentation of the safety and benefits of subconjunctival steroids for anterior nonnecrotizing scleritis. Although our experience using this mode of therapy extends beyond the . . . [Full Text of this Article]

Report of Cases

Group 1 (Patients Receiving 1 Injection With Intermediate-Term Follow-up [12-45 Months])

CASE 1

Group 2 (Patients Receiving Multiple Injections With Long-term Follow-up)

CASE 2

CASE 3

Group 3 (Patients With Severe Visual Disability or Intolerance After Standard Systemic Therapy)

CASE 4

Comment
Corresponding author: Frederick S. Brightbill, MD, Department of Ophthalmology and Visual Sciences, University of Wisconsin, 2870 University Ave, Suite 102, Madison, WI 53705.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Subconjunctival corticosteroid injection for the treatment of non-necrotising anterior scleritis
Sen et al.
Br. J. Ophthalmol. 2005;89:917-918.
FULL TEXT  

Regulation of Collagenase, Stromelysin, and Urokinase-Type Plasminogen Activator in Primary Pterygium Body Fibroblasts by Inflammatory Cytokines
Solomon et al.
IOVS 2000;41:2154-2163.
ABSTRACT | FULL TEXT